close
close

The venous thromboembolism treatment market is expected to reach USD 2.58 billion by 2034, with a constant annual growth rate of 3.9%

The venous thromboembolism treatment market is expected to reach USD 2.58 billion by 2034, with a constant annual growth rate of 3.9%

Venous thromboembolism treatment market

There is encouraging news in the fight against blood clots. The global market for the treatment of venous thromboembolism, valued at $1.76 billion In 2024, a significant achievement is expected USD 2.58 billion by 2034This means a steady growth trajectory at the level Compound annual growth rate (CAGR) of 3.9% over the next decade.

Venous thromboembolism, a medical condition characterized by the formation of blood clots in deep veins, is a major problem in the healthcare landscape. The FMI study highlights that more than 60% of VTE treatment demand is attributed to deep venous thrombosis, underscoring the urgent need for effective therapeutic solutions in this field.

Venous thromboembolism treatment includes segmented pneumatic compression pumps without gradient, segmented pneumatic compression pumps with calibrated gradient, lower pneumatic compression sleeves, non-segmented pneumatic compression pumps, permanent inferior vena cava filters, retrievable inferior vena cava filters, balloon embolectomy catheters, percutaneous thrombectomy devices, catheter-directed thrombolysis (CDT) devices, and upper pneumatic compression sleeves. Based on the disease indication, deep vein thrombosis is expected to account for a significant share of the overall global venous thromboembolism treatment industry.

Order a sample of this report now!

Poor reimbursement scenario in the face of high treatment costs limiting adoption

The overall growth of the global VTE treatment industry is driven by several factors. The first and foremost factor driving the global VTE treatment industry is the increasing prevalence of VTE disease. Other factors such as increasing rate of vena cava filter recovery, increasing healthcare awareness, presence of favorable reimbursement policies, and growing geriatric population are also responsible for the growth of the global VTE treatment industry.

Apart from the factors driving the global VTE treatment industry, there are several factors that may hinder the overall growth of the VTE treatment market. High costs associated with VTE treatment therapy, low reimbursement for some therapeutic devices, and poor insurance support are some of the major factors that are likely to hinder the growth of the global VTE treatment industry.

Drug-based treatments are gaining popularity across Europe

Although the increasing preference for drug-based VTE treatment is likely to hinder the market growth, next-generation drugs, including non-vitamin K antagonist oral anticoagulants (NOACs) such as dabigatran, rivaroxaban, apixaban, and edoxaban, are expected to increase the adoption rate of VTE treatment due to their improved efficacy. However, there are regional differences in this trend.

North America is expected to be a significant region in the global venous thrombosis treatment industry owing to the presence of well-developed healthcare infrastructure and numerous technological advancements in the region. The increasing incidence of venous thrombosis is also responsible for boosting the growth of the North America market. Treatment using mechanical and interventional prophylactic systems is expected to see increasing adoption in the North America region during the forecast period. Moreover, drug-based treatments are expected to gain popularity in the European region, which is likely to result in a decrease in the use of mechanical and interventional treatment methods in the region.

On the other hand, rising per capita healthcare expenditure is one of the macroeconomic factors that are likely to boost the market. Currently, certain changes in the socio-economic scenario can also lead to a significant growth in the global venous thrombosis treatment industry.

First league players account for almost 35% of the market revenue share

Some of the key manufacturers of VTE are mainly focused on innovation and launching new and advanced products. Major players in the global VTE industry are focusing on collaborations and acquisitions. For example, VTE is mainly used by hospitals, catheterization laboratories, and ambulatory surgery centers. Hospitals are expected to account for a significant share of revenue in the VTE market.

The report tracks some of the key companies operating in the global Venous Thrombosis Treatment industry such as ArjoHuntleigh AB, AngioDynamics, Cardinal Health Inc., BTG International Ltd., Stryker Corporation, DJO Global Inc., EKOS Corp, and Teleflex Inc., Boston Scientific Corp. many more companies are operating in the global Venous Thrombosis Treatment industry. AngioDynamics, Boston Scientific Corp., and Cardinal Health Inc. are expected to hold a significant share in the Venous Thrombosis Treatment market. These top-tier companies account for a share of around 35% in the global Venous Thrombosis Treatment industry.

Gain access to exclusive market information – buy now!

Venous Thromboembolism Treatment Market by Category By Product:

  • Pneumatic compression pumps without segments
  • Non-gradient pneumatic segmented compression pumps
  • Calibrated gradient segmented pneumatic compression pumps
  • Upper pneumatic compression sleeves
  • Pneumatic compression lower sleeves
  • Inferior vena cava permanent filters
  • Inferior vena cava filters that can be recovered
  • Balloon catheters for embolectomy
  • Percutaneous Thrombectomy Devices
  • Catheter-directed thrombolysis (CDT) devices

According to disease indication:

  • Deep vein thrombosis
  • Pulmonary embolism

By end user:

  • Hospitals
  • Catheterization laboratories
  • Outpatient Surgery Centers

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) has over 12 years of experience in the healthcare, medical devices and pharmaceutical industries. His curious and analytical nature has helped shape his career as a researcher.

Identifying key challenges faced by clients and developing robust, hypothesis-driven solutions to equip them with strategic decision-making capabilities comes naturally to him. His primary expertise includes go-to-market and expansion strategy, feasibility studies, competitive intelligence, and strategic transformation.

Sabyasachi, who holds a degree in microbiology, has published extensively in journals such as The Journal of mHealth, ITN Online and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, Stevie Award winner and member of the Greater New York Chamber of Commerce) offers in-depth insights into the factors driving market demand. FMI is a leading global provider of market intelligence, advisory services, consulting and events for the packaging, food and beverage, consumer technology, healthcare, industrial and chemical markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional and local expertise on various industry disciplines and trends in over 110 countries.

Contact us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Apartment 401, Newark, Delaware – 19713, USA
Phone: +1-845-579-5705
For sales inquiries: [email protected]
Website: https://www.futuremarketinsights.com
LinkedIn | Twitter| Blogs | YouTube